The digital lending platform is designed to aid lenders in rapidly expanding business operations as well as generating digital revenue streams by targeting new customer segments. 

Rufinamide oral suspension 40 mg/ml is a generic equivalent of Banzel oral suspension of Eisai Inc, which is used in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients of age one year and older. 

The company received LOA for pipe drinking water schemes from Namami Gange & Rural Water Supply Department in the state of Uttar Pradesh. 

The promoter plans to sell 2,40,00,000 equity shares of the company with an option to additionally sell 80,00,000 shares. The company has set a floor price of Rs 1,367 per share for the sale.

The company will manufacture Dexmedetomidine Hydrochloride in 0.9 per cent Sodium Chloride injection, in the strengths of 200 µg/50 ml and 400 µg/100 ml single doses in flexible containers (bags). The injection is said to launch in January 2021.

Bengaluru is a key market for the company and the project would help the company to deepen its presence across the country's leading real estate markets.

In phase 1 clinical trial, the company will study the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 in healthy human volunteers.

The manufacturing of the drug will take place at the company’s manufacturing facility in Chantilly (Virginia) and its launch is expected soon.

The company has made an investment of Rs 5,477 crore for the expansion. Upon completion, the company’s capacity will increase to 136.25 MTPA, making it the third-largest company in the world, outside China.

The company has received an order worth Rs 3,905 crore exclusive of GST in the month of November. Out of the four orders, one belongs to the water division amounting to Rs 848 crore and the remaining three orders belong to the building division worth Rs 3,057 crore.